Already from the beginning, the USA has a head start over Europe in every measurable variable for investors, according to the lobby organization European Federation of Pharmaceutical Industries and Associations.
This applies to everything from access to capital to the management of rights and how permit processes are handled.
"Now with the addition of tariffs, there are few incentives to invest in the EU and significant factors driving us to relocate to the USA", writes the organization.
According to a industry survey, it concerns 85 percent of investments and around 50 percent of research and development, to a total value of over 100 billion euros, that are at stake.
The organization includes, among others, pharmaceutical companies such as Bayer, Astra Zeneca and Novartis.
